title: Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.
abstract: Cholecystokinin (CCK) decreases meal size through activation of CCK-A receptors on vagal afferents. We tested the hypothesis that the selective CCK-A agonist GI181771X induces weight loss in obese patients. Patients with body mass index > or = 30 or > or = 27 kg/m2 with concomitant risk factors were randomized to 24-week, double-blind treatment with different GI181771X doses or matching placebo together with a hypocaloric diet. The primary efficacy end point was the absolute change in body weight. To monitor pancreatic and gallbladder effects, patients underwent abdominal ultrasound and magnetic resonance imaging before and after treatment. We randomized 701 patients to double-blind treatment. GI181771X did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers. Gastrointestinal side effects were more common with GI181771X than with placebo treatment, whereas hepatobiliary or pancreatic abnormalities did not occur. CCK-A by itself does not have a central role in long-term energy balance.
authors.affiliation: Franz-Volhard Clinical Research Center, Helios Klinikum and Medical Faculty of the Charité, Berlin, Germany. jens.jordan@charite.de
authors.forename: J
authors.initials: J
authors.lastname: Jordan
authors.forename: F L
authors.initials: FL
authors.lastname: Greenway
authors.forename: L A
authors.initials: LA
authors.lastname: Leiter
authors.forename: Z
authors.initials: Z
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Jacobson
authors.forename: K
authors.initials: K
authors.lastname: Murphy
authors.forename: J
authors.initials: J
authors.lastname: Hill
authors.forename: L
authors.initials: L
authors.lastname: Kler
authors.forename: R P
authors.initials: RP
authors.lastname: Aftring
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D031204:Caloric Restriction; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D005704:Gallbladder / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000187:drug effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010179:Pancreas / Q000187:drug effects; D043886:Receptor, Cholecystokinin A / Q000819:agonists* / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D019440:Anti-Obesity Agents; C488719:GI 181771X; D043886:Receptor, Cholecystokinin A; D001569:Benzodiazepines